Topic Novartis

Companies Novartis

News Novartis

• Ablynx's partner shows that a nanobody can elicit superior anti-tumour efficacy compared to conventional monoclonal antibody approaches

  Ablynx noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago by Novartis. The ability of TAS2 more

• Ablynx receives milestone payment as collaborator receives IND approval for a nanobody in oncology

  Ablynx announced that it has received a €400,000 milestone payment from its collaboration with Novartis. The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase I clinical trial for a Nanobody® licensed to No more

• 'Cancer Drug Market Will Reach $75 Billion in 2012' visiongain Report Predicts

  A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. The new study predicts that overall revenues for anti-cancer tr more

White papers Novartis

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications Novartis

• Author reply to Fujimi et al

  Author reply to Fujimi et al Content Type Journal Article Category Letter to the Editors Pages 1-2 DOI 10.1007/s00228-012-1276-8 Authors Richard A. Larson, University of Chicago, Chicago, IL, USA Ophelia Q. P. Yin, Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA more

• The Chemical Tuning of a Weak Zinc Binding Motif for Histone Deacetylase Using Electronic Effects

  Abstract The hydroxamic acid moiety is an effective metal‐binding warhead for a variety of metalloenzyme targets of interest to drug‐discovery. For the zinc‐containing histone deacetylase enzymes in particular, this chemical group has been widely incorporated and studied in the clinic. An alterna more

• Octreotide long-acting repeatable for acromegaly

  Acromegaly remains a therapeutic challenge for the endocrinologist. Among the available therapeutic options, octreotide long-acting repeatable (Sandostatin® LAR®, Novartis) plays a chief role, both as a primary therapy and as an adjuvant treatment after unsuccessful surgery. A plethora of papers and more

Market studies Novartis

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more

• Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteopenia Therapeutics market. The report identifies the more

Websites Novartis